Phase II/III study in children and adolescents with newly diagnosed B-cell precursor acute lymphoblastic leukemia: Protocol for a nationwide multicenter trial in Japan

Katsuyoshi Koh, Motohiro Kato, Akiko M. Saito, Akiko Kada, Hirohide Kawasaki, Yasuhiro Okamoto, Toshihiko Imamura, Keizo Horibe, Atsushi Manabe

Research output: Contribution to journalArticlepeer-review

20 Citations (Scopus)

Abstract

B-cell precursor acute lymphoblastic leukemia is the most common pediatric malignancy, but its treatment needs to be modified to cause low acute toxicity and few late complications with a high cure rate. In this trial, we will stratify patients with B-cell precursor acute lymphoblastic leukemia into standard, intermediate and high risk groups according to prognostic factors. In addition, we will establish an evaluation system for minimal residual disease that will enable us to stratify patients based on minimal residual disease in subsequent clinical trials. We will clarify the impact of dexamethasone/vincristine pulse therapy during maintenance therapy in the standard risk group, and intensive L-asparaginase therapy in the intermediate risk group. In the high risk group, usefulness of vincristine intensification will be assessed. This trial has been registered in the UMIN Clinical.

Original languageEnglish
Pages (from-to)684-691
Number of pages8
JournalJapanese journal of clinical oncology
Volume48
Issue number7
DOIs
Publication statusPublished - 01-07-2018
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint

Dive into the research topics of 'Phase II/III study in children and adolescents with newly diagnosed B-cell precursor acute lymphoblastic leukemia: Protocol for a nationwide multicenter trial in Japan'. Together they form a unique fingerprint.

Cite this